Toxicity of sorafenib: clinical and molecular aspects

Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats

(2009) Jian-Wei Gu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Management of hypertension in angiogenesis inhibitor-treated patients

(2009) H. Izzedine et al.   ANNALS OF ONCOLOGY

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

(2009) M Hennenberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

(2009) N. S. Azad et al.   CLINICAL CANCER RESEARCH

The pathogenic mechanisms of sorafenib-related diarrhea: Preliminary results

(2009) E.C. Lauritano et al.   DIGESTIVE AND LIVER DISEASE

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

(2009) Marcus Alexander Wörns et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

(2009) Jean Philippe Arnault et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

(2009) B. Blanchet et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism

(2009) Agnes Machnik et al.   NATURE MEDICINE

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

(2009) Francesco Torino et al.   Nature Reviews Clinical Oncology

Nævus éruptifs sous sorafénib

(2008) M. Bennani-Lahlou et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

(2008) M. E. Lacouture et al.   ANNALS OF ONCOLOGY

Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

(2008) Julien Autier et al.   ARCHIVES OF DERMATOLOGY

Sorafenib-Induced Eruptive Melanocytic Lesions

(2008) Heidi H. Kong et al.   ARCHIVES OF DERMATOLOGY

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

(2008) K Hoffmann et al.   BMC CANCER

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: Results from a phase I extension trial

(2008) H. Richly et al.   EUROPEAN JOURNAL OF CANCER

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

(2008) Caroline Robert et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial

(2008) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

(2008) Shenhong Wu et al.   LANCET ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

(2007) I. Tamaskar et al.   ANNALS OF ONCOLOGY